Postmenopausal patients, defined as: natural menopause for at least 1 year, surgical
ovariectomy, chemotherapy-induced amenorrhoea for at least 2 years.
Patients who have had surgical treatment for histologically confirmed breast cancer that
was nonmetastatic at the time of the initial diagnosis.
Patients whose tumour was hormone receptor positive (HR+, ER+ and/or PR+). Patients
initiated on Aromasin at least 2 months before inclusion but not more than 1 year.
Patients for whom Aromasin treatment is contraindicated. Presence of metastasis or a
contralateral tumour. Another adjuvant endocrine therapy. Another concomitant
antineoplastic treatment (except for Herceptin®). Participation in a clinical trial with
an investigational drug during the 30 days prior to enrolment in the study.